Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Certolizumab pegol Goel N; Stephens SMAbs 2010[Mar]; 2 (2): 137-47Certolizumab pegol (Cimzia((R))) is currently the only PEGylated anti-TNFalpha biologic approved for the treatment of rheumatoid arthritis and Crohn disease. The product, developed by UCB, is a humanized antigen-binding fragment (Fab') of a monoclonal antibody that has been conjugated to polyethylene glycol. Certolizumab pegol was approved as a treatment for rheumatoid arthritis in the EU, US and Canada in 2009, and as a treatment for Crohn disease in Switzerland in 2007 and the US in 2008. Certolizumab pegol is entering into an increasingly competitive marketplace, especially in rheumatoid arthritis, but clinical data demonstrate benefits across a range of clinical, radiographic and patient reported outcomes.|*Immunotherapy/economics/trends[MESH]|Antibodies, Monoclonal, Humanized[MESH]|Arthritis, Rheumatoid/*drug therapy/immunology[MESH]|Canada[MESH]|Certolizumab Pegol[MESH]|Clinical Trials as Topic[MESH]|Crohn Disease/*drug therapy/immunology[MESH]|Drug Approval[MESH]|European Union[MESH]|Humans[MESH]|Immunoglobulin Fab Fragments/pharmacology/*therapeutic use[MESH]|Marketing[MESH]|Polyethylene Glycols/pharmacology/*therapeutic use[MESH]|Tumor Necrosis Factor-alpha/antagonists & inhibitors/immunology[MESH]|United States[MESH] |
